These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 2127356)

  • 21. Interleukin 6 and plasma cell neoplasias.
    Hirano T; Kishimoto T
    Prog Growth Factor Res; 1989; 1(3):133-42. PubMed ID: 2491260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. All-trans-retinoic acid inhibits the development of mesangial proliferative glomerulonephritis in interleukin-6 transgenic mice.
    Shima Y; Iwano M; Yoshizaki K; Tanaka T; Kawase I; Nishimoto N
    Nephron Exp Nephrol; 2005; 100(1):e54-62. PubMed ID: 15795517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-6: a comprehensive review.
    Lotz M
    Cancer Treat Res; 1995; 80():209-33. PubMed ID: 8821579
    [No Abstract]   [Full Text] [Related]  

  • 24. Interleukin-6: molecular pathophysiology.
    Sehgal PB
    J Invest Dermatol; 1990 Jun; 94(6 Suppl):2S-6S. PubMed ID: 2191052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines.
    Murakami M; Kamimura D; Hirano T
    Immunity; 2019 Apr; 50(4):812-831. PubMed ID: 30995501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interleukin 6 (IL-6)].
    Dohi K; Iwano M; Horii Y
    Nihon Rinsho; 1992 Dec; 50(12):2916-20. PubMed ID: 1491446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin 6 (IL-6).
    Matsuda T; Hirano T
    Biotherapy; 1990; 2(4):363-73. PubMed ID: 2268501
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
    Suzuki H; Yasukawa K; Saito T; Goitsuka R; Hasegawa A; Ohsugi Y; Taga T; Kishimoto T
    Eur J Immunol; 1992 Aug; 22(8):1989-93. PubMed ID: 1639101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-6: structure-function relationships.
    Simpson RJ; Hammacher A; Smith DK; Matthews JM; Ward LD
    Protein Sci; 1997 May; 6(5):929-55. PubMed ID: 9144766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-1 and tumor necrosis factor: effector cytokines in autoimmune diseases.
    Dinarello CA
    Semin Immunol; 1992 Jun; 4(3):133-45. PubMed ID: 1320950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA.
    Okuno Y; Takahashi T; Suzuki A; Fukumoto M; Nakamura K; Fukui H; Koishihara Y; Ohsugi Y; Imura H
    Exp Hematol; 1992 May; 20(4):395-400. PubMed ID: 1568457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Interleukin-6 and its receptor].
    Matsuda T; Hirano T
    Tanpakushitsu Kakusan Koso; 1991 May; 36(7):1184-94. PubMed ID: 1908108
    [No Abstract]   [Full Text] [Related]  

  • 33. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
    Ohsugi Y
    Biol Pharm Bull; 2007 Nov; 30(11):2001-6. PubMed ID: 17978466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma.
    Chen YH; Shiao RT; Labayog JM; Modi S; Lavelle D
    Leuk Lymphoma; 1997 Sep; 27(1-2):11-23. PubMed ID: 9373192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.
    Kallen KJ
    Biochim Biophys Acta; 2002 Nov; 1592(3):323-43. PubMed ID: 12421676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interleukin 6 and disease].
    Kaisho T; Hirano T
    Ryumachi; 1991 Jun; 31(3):318-26. PubMed ID: 1948452
    [No Abstract]   [Full Text] [Related]  

  • 37. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
    Tanaka T; Narazaki M; Ogata A; Kishimoto T
    Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin 6 and its receptor in the immune response and hematopoiesis.
    Hirano T; Taga T; Matsuda T; Hibi M; Suematsu S; Tang B; Murakami M; Kishimoto T
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():155-66; discussion 166-7. PubMed ID: 2324554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of interleukin 6 in the growth of myeloma-derived cell lines.
    Barut BA; Zon LI; Cochran MK; Paul SR; Chauhan D; Mohrbacher A; Fingeroth J; Anderson KC
    Leuk Res; 1992 Oct; 16(10):951-9. PubMed ID: 1405708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines.
    Levy Y; Tsapis A; Brouet JC
    J Clin Invest; 1991 Aug; 88(2):696-9. PubMed ID: 1864979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.